Comment on ‘Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model‐Informed Drug Development Approach’ | Synapse
April 16, 2026Diabetes Obesity and Metabolism0 citations
Comment on ‘Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model‐Informed Drug Development Approach’
To provide feedback on the drug development approach for semaglutide used in treating obesity in adolescents.
Commentary on published research
Focus on efficacy, safety, and pharmacokinetics of semaglutide
No results reported from the authors' commentary
Abstract
The authors have nothing to report. The peer review history for this article is available at https://www.webofscience.com/api/gateway/wos/peer-review/10.1111/dom.70761.